Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has the Sotrovimab Or Xevudy Market Size Changed, over the years?
The market size for sotrovimab or xevudy has seen a significant surge, marked by XX% growth (HCAGR) in recent times. The said market is predicted to expand from $XX million in 2024 to $XX million in 2025, growing at a compound annual growth rate (CAGR) of XX%. The historic period’s growth can be tied to factors such as the spread of COVID-19, the growing demand for effective monoclonal antibody treatments, enhanced understanding of high-risk patient care, ascending government funding levels, and rising collaborations among pharmaceutical enterprises.
How Much Will the Sotrovimab Or Xevudy Market Be Worth in 2029?
In the coming years, the sotrovimab, also known as xevudy, market is projected to experience an XX (FCAGR) increase. By 2029, it is forecasted to expand to $XX million with a Compound Annual Growth Rate (CAGR) of XX%. The anticipated growth during the forecasted years can be associated with the surging appearance of novel COVID-19 strains, greater emphasis on monoclonal antibody therapies, the extension of healthcare facilities in emerging regions, increased government backing for epidemic readiness, and the expansion of telehealth services for treatment distribution. The major trends expected throughout the forecast period encompass improvements in vaccine production techniques, innovations in drug formulations, the incorporation of telehealth, advancements in technologies for antibody production, and progress in antibody engineering.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20383&type=smp
Which is the Largest Company in the Sotrovimab Or Xevudy Market?
Major companies operating in the sotrovimab or xevudy market are GSK plc; Vir Biotechnology Inc.
What Are the Main Market Drivers in the Sotrovimab Or Xevudy Industry?
The escalating number of COVID-19 incidents is anticipated to fuel the expansion of the sotrovimab or xevudy market in future. COVID-19, a disease instigated by the SARS-CoV-2 virus, propagates through respiratory droplets and results in symptoms ranging from a mild fever to significant respiratory complications. Its diffusion can be restrained through vaccination and good hygiene practices. The rising trend in COVID-19 cases is due to a variety of factors like emergence of new strains, depreciating immunity, relaxation of restrictions, indoor gatherings during seasons, and uneven distribution of vaccinations. Sotrovimab is utilized to treat high-risk COVID-19 patients by neutralizing the virus at an early stage, averting severe consequences such as hospitalization or death. For instance, a report by the Office for National Statistics, a government department for official statistics in the UK, stated in March 2023, that approximately 1.9 million people in the UK (2.9% of the population) reported having COVID. The majority (92%) had contracted COVID-19 more than 12 weeks prior, with 69% still suffering symptoms for over a year and 41% for more than two years. Hence, the escalating prevalence of COVID cases is set to spur the growth of the sotrovimab or xevudy market.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=20383&type=smp
How Is the Sotrovimab Or Xevudy Market Segments Structured?
The sotrovimab or xevudy market covered in this report is segmented –
1) By Indication: COVID-19 Early Treatment; Post-Exposure Prophylaxis
2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Pediatric; Adult; Geriatric
What Strategic Trends Are Transforming the Sotrovimab Or Xevudy Market?
One noteworthy trend in the sotrovimab or xevudy market involves making strategic investments to enhance research and development, augment production capabilities, and broaden drug availability. These collaborations play a vital role in expediting distribution and ensuring widespread availability, particularly in regions with higher needs. For example, in January 2022, a significant deal was announced by GSK plc, a UK-based pharmaceutical firm, and Vir Biotechnology Inc., a US-based biotechnology firm. They agreed upon additional purchases of sotrovimab, a monoclonal antibody approved for early COVID-19 treatment, with the US government. This deal underlines the continuous demand for effective therapies as the pandemic continues to mutate. Specifically, sotrovimab was developed for adults and adolescents at high risk of severe COVID-19 and provides an essential alternative for those not needing oxygen supplementation. This recent deal reflects a broader strategy by GSK and Vir to maintain sotrovimab’s accessibility despite the emergence of new virus strains.
Access The Full Report Here:
https://www.thebusinessresearchcompany.com/report/sotrovimab-or-xevudy-global-market-report
Which Global Regions Offer the Highest Growth in the Sotrovimab Or Xevudy Market?
North America was the largest region in the sotrovimab or xevudy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sotrovimab or xevudy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase The Full Report Today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=20383
This Report Delivers Insight On:
1. How big is the sotrovimab or xevudy market, and how is it changing globally?
2. Who are the major companies in the sotrovimab or xevudy market, and how are they performing?
3. What are the key opportunities and risks in the sotrovimab or xevudy market right now?
4. Which products or customer segments are growing the most in the sotrovimab or xevudy market?
5. What factors are helping or slowing down the growth of the sotrovimab or xevudy market?
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 2071930708
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model